Rigel Pharmaceuticals, Inc. (RIGL)
Largest Insider Buys in Sector
RIGL Stock Price History Chart
RIGL Stock Performance
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the …
Insider Activity of Rigel Pharmaceuticals, Inc.
Over the last 12 months, insiders at Rigel Pharmaceuticals, Inc. have bought $0 and sold $90,916 worth of Rigel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rigel Pharmaceuticals, Inc. have bought $688,400 and sold $76,674 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $688,400 was made by RODRIGUEZ RAUL R (CEO, President) on 2022‑06‑09.
List of Insider Buy and Sell Transactions, Rigel Pharmaceuticals, Inc.
| 2024-02-05 | Sale | CEO, President | 30,545 0.016% | $1.14 | $34,821 | +2.56% | ||
| 2024-02-05 | Sale | EVP & Chief Financial Officer | 7,027 0.0037% | $1.14 | $8,011 | +2.56% | ||
| 2024-02-05 | Sale | EVP, Chief Commercial Officer | 8,918 0.0047% | $1.14 | $10,167 | +2.56% | ||
| 2024-02-02 | Sale | CEO, President | 22,349 0.0116% | $1.13 | $25,261 | +5.26% | ||
| 2024-02-02 | Sale | EVP & Chief Financial Officer | 5,601 0.0029% | $1.13 | $6,327 | +5.26% | ||
| 2024-02-02 | Sale | EVP, Chief Commercial Officer | 5,601 0.0029% | $1.13 | $6,329 | +5.26% | ||
| 2023-02-06 | Sale | CEO, President | 20,340 0.012% | $1.75 | $35,595 | -26.90% | ||
| 2023-02-02 | Sale | EVP & Chief Financial Officer | 5,389 0.0029% | $1.66 | $8,946 | -28.81% | ||
| 2023-02-02 | Sale | EVP, Chief Commercial Officer | 5,388 0.0029% | $1.66 | $8,945 | -28.81% | ||
| 2023-02-02 | Sale | EVP & CMO | 5,389 0.0029% | $1.66 | $8,946 | -28.81% | ||
| 2022-06-09 | CEO, President | 1M 0.5572% | $0.69 | $688,400 | +76.88% | |||
| 2019-05-22 | EVP &Chief Financial Officer | 50,000 0.0311% | $2.13 | $106,544 | +2.44% | |||
| 2018-10-12 | Sale | Principal Accounting Officer | 10,000 0.006% | $3.12 | $31,200 | -26.61% | ||
| 2018-09-17 | Sale | EVP & Chief Medical Officer | 37,500 0.0231% | $3.50 | $131,250 | -31.38% | ||
| 2018-09-11 | EVP & Chief Commercial Officer | 50,000 0.0303% | $3.23 | $161,340 | -26.56% | |||
| 2018-09-10 | EVP & Chief Commercial Officer | 50,000 0.0301% | $3.28 | $164,210 | -28.05% | |||
| 2018-09-04 | Sale | EVP & Chief Medical Officer | 16,500 0.0101% | $3.51 | $57,861 | -31.20% | ||
| 2018-08-23 | EVP & Chief Commercial Officer | 100,000 0.0606% | $2.82 | $282,320 | -14.64% | |||
| 2018-08-17 | CEO, President | 114,000 0.0688% | $2.63 | $300,002 | -8.02% | |||
| 2018-07-02 | Sale | EVP & Chief Medical Officer | 5,000 0.0029% | $2.79 | $13,932 | -14.09% |
Insider Historical Profitability
| RODRIGUEZ RAUL R | CEO, President | 2036629 11.575% | $15.03 | 2 | 4 | +34.43% |
| Schorno Dean L | EVP & Chief Financial Officer | 402891 2.2898% | $15.03 | 1 | 3 | +2.44% |
| Flynn James E | 10 percent owner | 3204167 18.2107% | $15.03 | 1 | 1 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 646559 3.6747% | $15.03 | 1 | 1 | <0.0001% |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 215000 1.2219% | $15.03 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $22.73B | 87.48 | 15.36M | -10.18% | -$2.58B | 73.28 | |
| BlackRock | $21.9B | 84.28 | 14.8M | -2.63% | -$591.02M | 0.48 | |
| Morgan Stanley | $21.37B | 82.25 | 14.44M | -0.1% | -$21.1M | 1.58 | |
| The Vanguard Group | $13.86B | 53.35 | 9.37M | +4.63% | +$613.03M | 0.26 | |
| Soleus Capital Management, L.P. | $13.68B | 52.64 | 9.24M | -2.12% | -$296.88M | 56.68 |